Stockscreener 앱 받기
172.04
1.18%
-2.06
시간 외 거래:
172.00
-0.04
-0.02%
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Neurocrine Price Target Raised to $200.00/Share From $155.00 by Truist Securities - Moomoo
Form 4 Neurocrine Biosciences Inc For: 13 July By Investing.com - Investing.com Nigeria
Neurocrine Biosciences chief legal officer sells $1.79m in stock By Investing.com - Investing.com Nigeria
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine Biosciences chief legal officer sells $1.79m in stock - Investing.com
Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares - Stock Titan
NBIX Maintained by BMO Capital -- Price Target Raised to $170 - GuruFocus
Truist raises Neurocrine Bio stock price target on pipeline potential - Investing.com
Truist raises Neurocrine Bio stock price target on pipeline potential By Investing.com - Investing.com Australia
Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating - Moomoo
Reasons why investors should consider betting on Neurocrine stock - MSN
Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left? - simplywall.st
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen - ChartMill
NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart - ChartMill
Form 144 NEUROCRINE BIOSCIENCES For: 10 July By Investing.com - Investing.com South Africa
Form 144 NEUROCRINE BIOSCIENCES For: 10 July - Investing.com India
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) - Yahoo Finance
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline - FXEmpire
Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing - Moomoo
Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy? - simplywall.st
Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com - Investing.com India
Neurocrine Biosciences chief regulatory officer sells $2.6m stock - Investing.com
Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com - Investing.com South Africa
Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan - Stock Titan
Form 144 NEUROCRINE BIOSCIENCES For: 9 July By Investing.com - Investing.com Nigeria
10,000 NBIX shares listed for sale; recent Darin Lippoldt 10b5-1 trades (NBIX) - Stock Titan
Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Neurocrine's July 30 earnings call is scheduled for 4:30 p.m. ET - Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - The Independent Record
Neurocrine Biosciences stock stays supported by a growing movement disorder portfolio - AD HOC NEWS
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
Neurocrine Biosciences (NBIX) Stock Looks Reasonable After Its 90% Run - Sahm
Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs - Yahoo Finance
Neurocrine Biosciences (NBIX) Could Be 8% Undervalued Following New Phase 2 Study - Yahoo Finance
Neurocrine Biosciences (NBIX) Starts Phase 2 CAH Study In Children Under 4 - Yahoo Finance
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight - Yahoo Finance
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo
Neurocrine Biosciences outlines its neurology focus as a mid-cap biotech name - AD HOC NEWS
Insider option exercise and 10b5-1 sales at NBIX (NBIX) - Stock Titan
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - AOL.com
Neurocrine Biosciences stock hits all-time high at 176.1 USD By Investing.com - Investing.com Nigeria
Neurocrine Biosciences stock hits all-time high at 176.1 USD - Investing.com
Neurocrine Biosciences stock and its role in neurological treatments - AD HOC NEWS
RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating - Moomoo
Reasons Why Investors Should Consider Betting on Neurocrine Stock - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside - DirectorsTalk Interviews
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
0.49%
1.63%
자본화:
|
볼륨(24시간):